Corebridge Financial Inc. Has $826,000 Position in Xencor, Inc. (NASDAQ:XNCR)

Corebridge Financial Inc. increased its stake in shares of Xencor, Inc. (NASDAQ:XNCR) by 5.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 35,946 shares of the biopharmaceutical company’s stock after purchasing an additional 1,743 shares during the quarter. Corebridge Financial Inc. owned approximately 0.05% of Xencor worth $826,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Sanctuary Advisors LLC acquired a new position in shares of Xencor during the third quarter worth $540,000. Barclays PLC increased its holdings in Xencor by 100.7% in the 3rd quarter. Barclays PLC now owns 155,568 shares of the biopharmaceutical company’s stock worth $3,128,000 after purchasing an additional 78,066 shares in the last quarter. Jane Street Group LLC raised its position in Xencor by 18.6% in the third quarter. Jane Street Group LLC now owns 168,431 shares of the biopharmaceutical company’s stock valued at $3,387,000 after purchasing an additional 26,473 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Xencor by 1.2% during the third quarter. Geode Capital Management LLC now owns 1,455,350 shares of the biopharmaceutical company’s stock valued at $29,273,000 after purchasing an additional 17,658 shares in the last quarter. Finally, Principal Financial Group Inc. grew its holdings in shares of Xencor by 16.5% during the fourth quarter. Principal Financial Group Inc. now owns 340,145 shares of the biopharmaceutical company’s stock worth $7,817,000 after purchasing an additional 48,229 shares during the last quarter.

Analysts Set New Price Targets

A number of brokerages recently issued reports on XNCR. Wells Fargo & Company dropped their price objective on shares of Xencor from $37.00 to $33.00 and set an “overweight” rating for the company in a report on Friday, February 28th. StockNews.com downgraded shares of Xencor from a “hold” rating to a “sell” rating in a research note on Friday, March 14th. One research analyst has rated the stock with a sell rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Xencor presently has a consensus rating of “Moderate Buy” and an average price target of $34.38.

Xencor Trading Down 2.6 %

NASDAQ:XNCR opened at $8.69 on Friday. Xencor, Inc. has a 52 week low of $8.45 and a 52 week high of $27.24. The firm’s fifty day moving average is $14.51 and its 200-day moving average is $19.69. The firm has a market cap of $612.31 million, a P/E ratio of -2.72 and a beta of 0.90. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.23 and a current ratio of 6.23.

Xencor (NASDAQ:XNCR) last issued its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.62) EPS for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.19. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The business had revenue of $52.79 million for the quarter, compared to analysts’ expectations of $17.14 million. Equities analysts expect that Xencor, Inc. will post -3.68 earnings per share for the current year.

Xencor Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.